Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First FDA Center Of Excellence For Regulatory Science Looks At Nanotechnology

This article was originally published in The Pink Sheet Daily

Executive Summary

National Center for Toxicological Research signs agreement setting up CERS in Arkansas.

You may also be interested in...



FDA Advisors Want More Data On Nanotech Sunscreens

Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s knowledge of pharmaceutical firms’ use of nanotechnology still is developing, but maintain the products are safe.

FDA Advisors Want More Data On Nanotech Sunscreens

Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s understanding of how pharmaceutical firms are using nanotechnology is still developing, but they maintain that currently marketed products are safe.

Foreign Regulator Exchange Program Contemplated By U.S. State Department

FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel